General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Status:
Concluded with an LOI
Manufacturer:
Lundbeck Canada Inc.
Indication:
Major Depressive Disorder
Last updated December 3, 2020
Status:
Concluded with an LOI
Manufacturer:
Merck Canada Inc.
Indication:
Renal Cell Carcinoma
Last updated December 1, 2020
Status:
Concluded with an LOI
Manufacturer:
Alnylam Netherlands B.V.
Indication:
Hereditary transthyretin-mediated amyloidosis
Last updated November 30, 2020
Status:
Concluded with an LOI
Manufacturer:
Santen Incorporated
Indication:
Severe Vernal Keratoconjunctivitis
Last updated November 20, 2020
Kadcyla (trastuzumab emtansine)
Status:
Concluded with an LOI
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
Early Breast Cancer
Last updated November 5, 2020
Status:
Concluded with an LOI
Manufacturer:
Sanofi-Aventis Canada Inc.
Indication:
Cutaneous Squamous Cell Carcinoma
Last updated November 4, 2020
Status:
Concluded with an LOI
Manufacturer:
Amgen Canada Inc.
Indication:
Ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease and Ulcerative Colitis
Last updated November 2, 2020
Status:
Concluded with an LOI
Manufacturer:
Shire Pharma Canada ULC
Indication:
Hereditary Angioedema
Last updated October 30, 2020
Status:
Concluded with an LOI
Manufacturer:
Shire Pharma Canada ULC
Indication:
Short Bowel Syndrome (SBS)
Last updated October 28, 2020
Status:
Negotiations were not pursued
Manufacturer:
Sanofi-Aventis Canada Inc.
Indication:
Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
Last updated October 23, 2020